VC-backed Pulmatrix touts inhaled drug tech's delivery of Advair

Pulmatrix, which has pulled in tens of millions in venture capital from blue chip backers, has shown in lab tests that its inhaled dry power drug tech called iSperse beat a typical formulation of GlaxoSmithKline's ($GSK) big-selling treatment Advair in delivering "an effective therapeutic dose." The Lexington, MA-based firm--which was co-founded by MIT bioengineer extraordinaire Bob Langer--said that the results of the experiments have helped it move forward with development of the inhaled delivery tech in a variety of disease such as cystic fibrosis, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD). Release